10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
13.32
-0.25 (-1.84%)
Nov 20, 2024, 4:00 PM EST - Market closed
10x Genomics Revenue
10x Genomics had revenue of $151.65M in the quarter ending September 30, 2024, a decrease of -1.30%. This brings the company's revenue in the last twelve months to $629.74M, up 6.56% year-over-year. In the year 2023, 10x Genomics had annual revenue of $618.73M with 19.81% growth.
Revenue (ttm)
$629.74M
Revenue Growth
+6.56%
P/S Ratio
2.53
Revenue / Employee
$500,193
Employees
1,259
Market Cap
1.61B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Teladoc Health | 2.59B |
Clover Health Investments | 2.12B |
GoodRx Holdings | 790.39M |
Kiniksa Pharmaceuticals International, | 384.10M |
Certara | 372.80M |
Immunocore Holdings | 296.31M |
Arvinas | 161.10M |
Xencor | 85.16M |
TXG News
- 13 days ago - 10x Genomics to Present at the Wolfe Research 2024 Healthcare Conference - PRNewsWire
- 21 days ago - TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative - PRNewsWire
- 21 days ago - These Analysts Boost Their Forecasts On 10x Genomics After Q3 Results - Benzinga
- 22 days ago - 10x Genomics, Inc. (TXG) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 22 days ago - 10x Genomics Reports Third Quarter 2024 Financial Results - PRNewsWire
- 5 weeks ago - 10x Genomics Delivers 'Single Cell for a Single Cent' with New Chromium Launches - PRNewsWire
- 5 weeks ago - 10x Genomics: Deciphering The Preliminary Q3 Earnings - Seeking Alpha
- 6 weeks ago - 10x Genomics Announces Preliminary Select Third Quarter 2024 Results - PRNewsWire